Roxane Labs Recalls Azathioprine Tablets

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Roxane Laboratories (Columbus, OH), a Boehringer Ingelheim company, is conducting a voluntary recall in the United States and Puerto Rico of a single manufacturing lot of "Azathioprine"tablets, USP 50 mg.

Roxane Laboratories (Columbus, OH, www.roxane.com), a Boehringer Ingelheim company,is conducting a voluntary recall in the United States and Puerto Ricoof a single manufacturing lot of azathioprine tablets, USP 50 mg. Thecompany ordered the recall after discovering that a single bottleof azathioprine, which had not been dispensed to a patient, containedMethotrexate tablets, USP 2.5 mg, which would cause "serious toxiceffects" and even death at high doses, if taken in accordance withdosing instructions that may be prescribed for azathioprine. The companyis working with FDA on this recall, and no related injuries have beenreported to date.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content